Analyst picks & changes

Cephalon Inc.


Chiron Corp.


Analysts were virtually — but not quite — unanimous in their rave reviews of data from CEPH's Phase II/III trial of Myotrophin


in amyotrophic lateral sclerosis (see BioCentury Extras June 12 and 13).

Peter Ginsberg of Vector Securities International expects Myotrophin to rapidly penetrate the $250 million U.S. ALS market because there's no approved treatment, the disease is almost uniformly

Read the full 688 word article

How to gain access

Continue reading with a
two-week free trial.